Nightstar Therapeutics PLC Sponsored ADR (NITE) Forecasted to Earn Q3 2017 Earnings of ($0.19) Per Share

Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) – Equities research analysts at Jefferies Group issued their Q3 2017 earnings per share (EPS) estimates for Nightstar Therapeutics PLC Sponsored ADR in a report issued on Monday. Jefferies Group analyst M. Yee forecasts that the company will post earnings of ($0.19) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $25.00 target price on the stock. Jefferies Group also issued estimates for Nightstar Therapeutics PLC Sponsored ADR’s Q4 2017 earnings at ($0.16) EPS, FY2017 earnings at ($0.67) EPS, FY2018 earnings at ($1.34) EPS, FY2019 earnings at ($1.45) EPS and FY2020 earnings at ($1.80) EPS.



NITE has been the subject of several other research reports. Wedbush started coverage on shares of Nightstar Therapeutics PLC Sponsored ADR in a report on Monday. They issued an “outperform” rating and a $19.00 target price for the company. Leerink Swann started coverage on shares of Nightstar Therapeutics PLC Sponsored ADR in a report on Monday. They issued an “outperform” rating and a $25.00 target price for the company. Finally, BMO Capital Markets started coverage on shares of Nightstar Therapeutics PLC Sponsored ADR in a report on Monday. They issued an “outperform” rating and a $30.00 target price for the company.

WARNING: “Nightstar Therapeutics PLC Sponsored ADR (NITE) Forecasted to Earn Q3 2017 Earnings of ($0.19) Per Share” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/10/27/nightstar-therapeutics-plc-sponsored-adr-nite-forecasted-to-earn-q3-2017-earnings-of-0-19-per-share.html.

Nightstar Therapeutics PLC Sponsored ADR (NITE) opened at 19.65 on Wednesday. Nightstar Therapeutics PLC Sponsored ADR has a 1-year low of $14.56 and a 1-year high of $24.93. The stock’s 50 day moving average is $18.94 and its 200 day moving average is $18.94. The firm’s market capitalization is $552.18 million.

A hedge fund recently bought a new stake in Nightstar Therapeutics PLC Sponsored ADR stock. Nationwide Fund Advisors bought a new stake in Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 62,300 shares of the company’s stock, valued at approximately $1,196,000. Nationwide Fund Advisors owned about 0.22% of Nightstar Therapeutics PLC Sponsored ADR at the end of the most recent reporting period.

About Nightstar Therapeutics PLC Sponsored ADR

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Receive News & Ratings for Nightstar Therapeutics PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply